Trial reportWorld journal of urology2026
Tamsulosin versus tamsulosin plus tolterodine for the treatment of distal ureteral stones.
Trial report in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to compare the efficacy of tamsulosin monotherapy versus tamsulosin combined with tolterodine for facilitating the expulsion of distal ureteral stones.
methodsA prospective, randomized controlled trial was conducted between 2022 and 2023 at the Urology Clinic of Imam Reza Hospital, Ardabil. A total of 120 patients diagnosed with distal ureteral stones (4-10 mm in size) were randomized into two groups: Group A received 0.4 mg tamsulosin daily, and Group B received 0.4 mg tamsulosin daily plus 2 mg tolterodine twice daily. Treatment duration was up to 4 weeks. Primary outcomes included stone expulsion rate and expulsion time. Secondary outcomes comprised pain control (visual analog scale, VAS), analgesic requirement, and incidence of side effects.
resultsThe two groups were comparable at baseline in terms of demographic and stone characteristics. The stone expulsion rate was significantly higher in Group B (tamsulosin + tolterodine) at 83.3% (50/60) compared to Group A (tamsulosin alone) at 66.7% (40/60) (p = 0.03). The mean stone expulsion time was also significantly shorter in Group B (10.5 ± 3.2 days) compared to Group A (14.8 ± 4.1 days) (p < 0.001). Patients in Group B reported lower mean pain scores (VAS) and required less rescue analgesia. The incidence of adverse effects was comparable between the groups, with dry mouth being slightly more common in Group B.
conclusionThe combination of tamsulosin and tolterodine demonstrated superior efficacy in terms of stone expulsion rate and reduced expulsion time for distal ureteral stones compared to tamsulosin monotherapy. This combination therapy may offer a more effective medical expulsive therapy option for patients with distal ureteral calculi.
Indexed as
Identifiers
42667316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.